GeoVax Labs (NASDAQ:GOVX) Upgraded to “Sell” at Wall Street Zen

GeoVax Labs (NASDAQ:GOVX) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms have also recently weighed in on GOVX. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Stock Performance

NASDAQ GOVX opened at $1.22 on Friday. The firm’s fifty day moving average price is $1.63 and its two-hundred day moving average price is $3.20. The stock has a market cap of $4.23 million, a PE ratio of -0.06 and a beta of 3.62. GeoVax Labs has a fifty-two week low of $0.96 and a fifty-two week high of $34.75.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share for the quarter. As a group, sell-side analysts predict that GeoVax Labs will post -8.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Several institutional investors and hedge funds have recently made changes to their positions in GOVX. Sabby Management LLC acquired a new stake in shares of GeoVax Labs in the third quarter valued at about $313,000. Renaissance Technologies LLC acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at about $104,000. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at about $99,000. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs in the third quarter valued at about $253,000. Finally, HRT Financial LP acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.